Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 4Uterine Cervical Neoplasms 2Myelodysplastic Syndromes 2Leukemia 2Rectal Neoplasms 1Radiation Injuries 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma 1Lichen Planus, Oral 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Erectile Dysfunction 1Drug-Related Side Effects and Adverse Reactions 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Erythropoietin × Clear all
NCT05704894 2023-01-30

Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens

Blau Farmaceutica S.A.

Phase 3 Unknown
320 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡